

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



PegBio Co., Ltd.

派格生物醫藥(杭州)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2565)

**VOLUNTARY ANNOUNCEMENT
NOTICE ABOUT VOLUNTARY EXTENSION OF LOCK-UP PERIOD
GIVEN BY A CORNERSTONE INVESTOR**

This announcement is made by PegBio Co., Ltd. (the “**Company**”) on a voluntary basis.

References are made to the prospectus of the Company dated May 19, 2025 and the announcement of final offer price and allotment results of the Company dated May 26, 2025 in relation to, among others, (i) the cornerstone investment agreement entered into between the Company and Yizekangrui Medical (HK) Limited (益澤康瑞醫藥(香港)有限公司) (the “**Cornerstone Investor**”); and (ii) the Cornerstone Investor’s lock-up undertaking in respect of a total of 9,584,500 H shares of the Company during the period of six months from and including the Listing Date (the “**Original Lock-up Period**”). The last day of the Original Lock-up Period falls on November 26, 2025. As of the date of this announcement, the Cornerstone investor held a total of 9,584,500 H shares, representing approximately 3.43% of the total issued H shares of the Company (the “**Relevant H Shares**”).

Recently, the Company received a notice from the Cornerstone Investor, pursuant to which, the Cornerstone Investor agreed not to reduce its holding of any of the Relevant H Shares in any manner from the expiry of the Original Lock-up Period until December 31, 2025 (the “**Lock-up Extension**”). The Company believes that the Lock-up Extension indicates the Cornerstone Investor’s confidence in the Company’s future prospect, grounded on its research and development capability in advancing its technology and its significant progress towards significant clinical milestones. The Cornerstone Investor will also conduct ongoing reviews of the Company’s performance and may consider further extensions of the lock-up period based on real-time development and milestones achieved.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
PegBio Co., Ltd.
Michael Min XU
*Chairman of the Board, Executive Director
and General Manager*

Hong Kong, November 26, 2025

As of the date of this announcement, the board of directors of the Company comprises: (i) Dr. Michael Min XU and Ms. Xiaojun WANG as executive directors; (ii) Dr. Xiangjun ZHOU, Dr. Yuhong XU, Ms. Ting ZHAI and Mr. Hongkai LI as non-executive directors; and (iii) Dr. Jiancun ZHANG, Dr. Yangyang CHEN and Ms. Xinpeng FAN as independent non-executive directors.